Breaking News, Collaborations & Alliances

Allergan and Novartis in Clinical Collaboration

Will evaluate use of Allergan's cenicriviroc and Novartis lead FXR agonist to treat NASH

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Allergan has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH). The Phase 2b study will assess the safety, efficacy and tolerability of this multi-therapy treatment approach for NASH. “Our clinical collaboration with Novartis brings together our collective scientific and development expertise in NASH to focus on multi-t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters